RABAT, July 8 – Moroccan medical technology company T2S Group Holding has received approval from the Moroccan Capital Market Authority (AMMC) to proceed with its initial public offering (IPO), marking a significant milestone in the company’s expansion strategy.
The transaction, valued at approximately MAD 1.1 billion ($117 million), combines a public capital increase with the sale of existing shares, providing the company with fresh funding while broadening its shareholder base.
Under the proposed structure, around MAD 350 million ($37 million) will be raised through the issuance of new shares, while approximately MAD 750 million ($80 million) will come from the sale of shares held by existing shareholders.
The IPO is designed to strengthen T2S Group’s financial position, enhance its visibility in capital markets and support its long-term growth strategy as demand for healthcare technology continues to rise across Africa.
Founded in 1992, T2S Group has grown into one of Morocco’s leading MedTech companies, providing medical equipment, technical services and industrial solutions to hospitals and healthcare providers.
The company operates across several specialised healthcare segments, including medical imaging, oncology equipment, operating theatre technologies, laboratory diagnostics, nuclear medicine products, minimally invasive surgical devices and digital hospital systems.
Beyond supplying medical equipment, the company also provides installation, maintenance and long-term technical support, enabling healthcare institutions to maximise the performance and lifespan of critical medical technologies.
T2S Group has established partnerships with more than 40 international medical technology manufacturers, allowing it to offer a portfolio of over 8,000 medical products.
The company has also expanded beyond Morocco, building operations in more than 20 African countries through a centralised logistics platform supported by a workforce of over 400 employees.
Looking ahead, T2S Group plans to expand its presence across the continent by introducing new high-value medical technologies, strengthening its core business segments and pursuing strategic acquisitions where suitable opportunities arise.
The IPO is expected to provide the financial resources needed to accelerate these ambitions while positioning the company to benefit from rising healthcare investment, demographic growth and increasing demand for advanced medical technologies across Africa.
